Last updated: February 13, 2026
Overview
NDC 62332-0519 represents Abaloparatide, a synthetic peptide analog utilized primarily for the treatment of osteoporosis in postmenopausal women at high risk for fractures. Market access, competitive landscape, and pricing dynamics are influenced by regulatory approval, manufacturing costs, and reimbursement policies.
Market Landscape
-
Indication and Patient Population: The drug targets osteoporosis, affecting roughly 200 million women worldwide. The U.S. accounts for the largest market, with an estimated 20 million women with postmenopausal osteoporosis, of whom approximately 1 million are characterized as high risk for fracture.
-
Market Penetration: Abaloparatide (marketed as Tymlos by Radius Health) competes with established treatments such as teriparatide (Forteo), denosumab (Prolia), and bisphosphonates. It has secured FDA approval since April 2017 for the treatment of osteoporosis.
-
Sales Data: Globally, Abaloparatide recorded sales of approximately $150 million in 2022. Growth is constrained by market penetration, insurance coverage, and patient acceptance. U.S. sales constitute over 75% of revenue.
-
Manufacturing and Supply Chain: The production involves peptide synthesis, with a market-standard manufacturing cost estimated around $500–$1,000 per 30-day supply. Cost factors include raw materials, peptide stability, and formulation.
Pricing Dynamics
-
US List Price: The average wholesale price (AWP) for Abaloparatide therapy is approximately $4,150 per 30-day supply. Net prices after rebates and discounts are likely 20–30% lower (~$2,900–$3,300).
-
Pricing Comparison: Compared to teriparatide (Forteo), with list prices around $4,200 per month, Abaloparatide is priced competitively but remains premium compared to generic bisphosphonates ($20–$100/month).
-
Reimbursement Policies: Medicare and commercial payers typically reimburse at or near the list price, impacting net revenue and affordability for patients.
Price Projections (Next 3-5 Years)
| Year |
Estimated US List Price |
Expected Market Penetration |
Notes |
| 2023 |
$4,150 |
25% of target population |
Steady demand, limited direct competition |
| 2024 |
$4,200 |
30% of target population |
Slight price increase, new formulary agreements |
| 2025 |
$4,300 |
40% of target population |
Increased insurance coverage, physician adoption |
| 2026 |
$4,400 |
50% of target population |
Competition from biosimilars unlikely |
| 2027 |
$4,500 |
55% of target population |
Market saturation approaches |
Factors Influencing Price Trends
-
Patent and IP Status: Patent protections extending into 2030 limit biosimilar competition. Patent cliff would potentially enable generic or biosimilar entrants, driving prices down.
-
Market Competition: The adoption rate of biosimilars, if approved, will influence pricing pressure. As of 2023, biosimilar development for peptide drugs remains limited.
-
Regulatory Changes: CMS policies and Medicare Part D formulary negotiations will influence net reimbursement margins.
-
Economic Environment: Inflation, raw material costs, and healthcare policy shifts toward cost containment may restrain or moderate price increases.
Implications for Stakeholders
-
Pharmaceutical Developers: Maintaining exclusivity and patent protections is critical for sustained pricing power.
-
Payers: Negotiating volume-based discounts and formulary placements are central strategies to manage costs.
-
Patients: High list prices necessitate copay assistance and insurance coverage to improve accessibility.
Summary
Abaloparatide's market pricing maintains a premium position given its niche indication and limited direct competition. Price stability over the next several years relies on patent protections and the pace of biosimilar development. Reimbursement policies significantly influence net revenue and patient access. Manufacturers should monitor patent expiry timelines and biosimilar developments that threaten market share.
Key Takeaways
- Abaloparatide's US list price remains around $4,150 per month.
- Market growth in the next 5 years is projected at 10–15%, contingent on coverage and competition.
- Patent protection extends into the early 2030s; biosimilar competition is limited currently.
- Reimbursement negotiations are central to profitability and patient access.
- Cost containment policies could moderate future price increases.
FAQs
-
What is the current market size for Abaloparatide?
The global market generated approximately $150 million in 2022, driven mainly by the US.
-
How does the price compare to competitor drugs?
It is comparable to teriparatide (Forteo) at around $4,200/month but is positioned as a premium treatment.
-
When might biosimilar competition affect pricing?
Patent expiry is expected around 2030, which could open the market to biosimilars, potentially reducing prices.
-
What factors could influence future price adjustments?
Patent protection, biosimilar entry, insurance coverage, and healthcare policy changes.
-
How does reimbursement impact net revenue?
Reimbursement policies, especially Medicare and commercial payers, generally reimburse near list price, affecting profit margins.
References
[1] IQVIA, "Worldwide Drug Market Estimates," 2022.
[2] FDA, "Abaloparatide (Tymlos) Approval Documentation," 2017.
[3] Retail Pharmacy Pricing Data, April 2023.
[4] CMS Reimbursement Policy documents, 2023.
